Powering the Future of Targeted Radioligand Therapy
Eckert & Ziegler is supporting the advancement of cancer treatment with comprehensive, GMP-compliant solutions for the development and production of alpha-emitting radiopharmaceuticals. With decades of expertise in radiochemistry and a global network of facilities, we are uniquely positioned to support radiopharmaceutical companies, research institutions, and nuclear medicine professionals in the growing field of Targeted Alpha Therapy (TAT).
Alpha particles deliver high-energy radiation with a short path length, making them ideal for selectively destroying tumor cells while sparing surrounding healthy tissue. Actinium-225 (Ac-225) and Lead-212 (Pb-212) are at the forefront of this innovation, and Eckert & Ziegler is proud to be enabling their clinical use and supporting you in overcoming the unique challenges associated with their use.
Eckert & Ziegler is one of the first commercial suppliers of Actinium-225 for pharmaceutical applications. Our production facilities in Europe, North America, and soon Asia will ensure a secure, scalable, and GMP-grade supply of Ac-225 for pre-clinical development, clinical trials. Supply for future commercial use is planned.
Eckert & Ziegler provides comprehensive contract development and manufacturing (CDMO) services for radiopharmaceuticals labeled with alpha-emitting isotopes such as Actinium-225 and Lead-212. Our global GMP-compliant facilities support the reliable development, synthesis, and scale-up of alpha-conjugates for clinical and commercial use.
Synthesis processes with Ac-225 (publication) and Pb-212 (publication) were successfully transferred to Modular-Lab eazy, showing excellent yield and reproducibility. Its compact, cassette-based design reduces radioactive waste and enables automated, GMP-compliant workflows. For R&D, the flexible Modular-Lab PharmTracer adapts to your specific synthesis needs (publication).
Quality control of alpha-emitting radiopharmaceuticals presents unique challenges, including complex decay chains and strict regulatory expectations. Eckert & Ziegler addresses these pain points with a suite of purpose-built QC solutions designed for precision, compliance, and efficiency.
Working with alpha emitters requires the utmost attention to detail. Eckert & Ziegler offers a wide range of customizable hot cells and processing solutions for every step of radiopharmaceutical handling, including isotope production, labeling, dispensing, and sterile filtration.
With facilities across Europe, North America, and soon Asia, Eckert & Ziegler ensures timely, compliant delivery of alpha emitters and radiopharmaceuticals to your doorstep.
Whether you’re in pre-clinical research, launching a clinical trial or scaling for commercial production, Eckert & Ziegler offers the technology, expertise, and reliability you need to succeed in alpha therapy. Contact us using the form below and let’s talk about kick-starting your project!
